Sign in to view content

Efficacy, Safety, and Durability of Faricimab in Diabetic Macular Edema (DME): One-Year Results From the Phase 3 YOSEMITE and RHINE Trials

Caroline Baumal, MD, FASRS

Video
Published 2021

Related

Variability of Retinal Thickness in Diabetic macular edema (DME) Patients Treated with 0.19mg Fluocinolone Acetonide (FAc, ILUVIEN).
Christopher D. Riemann, MD
On Demand Cases, Courses, and Papers
2019
Personalized Treatment Interval Dosing Dynamics Over 2 Years in the Phase 3 YOSEMITE and RHINE Trials of Faricimab in Diabetic Macular Edema
John W. Kitchens, MD
Annual Meeting Talks
2022
Interim 12-Month Results from PALADIN in Diabetic Macular Patients Receiving ILUVIEN: Analysis of the Prior Dexamethasone Cohort
Daniel F. Kiernan, MD, FACS
On Demand Cases, Courses, and Papers
2019

Category: Diabetic Retinopathy

See more